Press release
Thyroid Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Stay ahead with the latest insights! Download DelveInsight's comprehensive Thyroid Cancer Pipeline Report to explore emerging therapies, key Thyroid Cancer Companies, and future Thyroid Cancer treatment landscapes @ Thyroid Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Thyroid Cancer Pipeline Report
* On 13 August 2025, Novartis Pharmaceuticals announced a phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid cancer who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy. After eligibility assessment, approximately 150 patients will be randomized in a 2:1 ratio to either dabrafenib plus trametinib or placebo.
* On 13 August 2025, Children's Hospital of Philadelphia conducted a study to evaluate the efficacy and safety of the combination of larotrectinib followed by 131I therapy for patients with NTRK fusion differentiated thyroid cancer. The primary Phase II objective will be to evaluate the pulmonary structural response rate at 18 months to the combination of larotrectinib given for 6-months followed by 131I therapy.
* DelveInsight's Thyroid Cancer pipeline report depicts a robust space with 50+ active players working to develop 51+ pipeline therapies for Thyroid Cancer treatment.
* The leading Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories , and others.
* Promising Thyroid Cancer Therapies such as Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
Discover how the Thyroid Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Thyroid Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Thyroid Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Thyroid Cancer Emerging Drugs
* rhTSH: Suzhou Zelgen Biopharmaceuticals
Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the resultant metabolic disturbance, and without the drawbacks associated with the use of bovine TSH. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with thyroid cancer.
* Nivolumab: Bristol-Myers Squibb
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with thyroid cancer.
* RX208: Suzhou NeuPharma
RX208 is a potential "best-in-class" BRAF V600E inhibitor with a proprietary novel chemical structure that is different from other marketed BRAF inhibitors. It exhibited high bioavailability and excellent anti-tumor efficacy in preclinical studies. Early clinical data demonstrated preliminary efficacy and good safety and tolerability in patients with cancer, warranting further clinical development. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with thyroid cancer.
* AIC100: AffyImmune Therapeutics
AffyImmune's lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100's CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity. Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Thyroid Cancer.
The Thyroid Cancer pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Thyroid Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Thyroid Cancer Treatment.
* Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Thyroid Cancer market.
Get a detailed analysis of the latest innovations in the Thyroid Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Thyroid Cancer Unmet Needs [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Thyroid Cancer Companies
AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Thyroid Cancer Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Download DelveInsight's latest report to gain strategic insights into upcoming Thyroid Cancer Therapies and key Thyroid Cancer Developments @ Thyroid Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Thyroid Cancer Pipeline Report
* Coverage- Global
* Thyroid Cancer Companies- AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
* Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
* Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Thyroid Cancer drug development? Find out in DelveInsight's exclusive Thyroid Cancer Pipeline Report-access it now! @ Thyroid Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Thyroid Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Thyroid Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* rhTSH: Suzhou Zelgen Biopharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Nivolumab: Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AIC100:Affyimmune Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Thyroid Cancer Key Companies
* Thyroid Cancer Key Products
* Thyroid Cancer- Unmet Needs
* Thyroid Cancer- Market Drivers and Barriers
* Thyroid Cancer- Future Perspectives and Conclusion
* Thyroid Cancer Analyst Views
* Thyroid Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=thyroid-cancer-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Thyroid Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4158895 • Views: …
More Releases from ABNewswire
Worldle Goes Gaeilge: Global Hit Game Adds Irish Language, Announced at NEXUS Ir …
DUBLIN, Ireland - Oct 2, 2025 - Today at the NEXUS Irish Games Industry Conference, Games publisher Teuteuf Games announced a significant update for its viral geography game, Worldle: the addition of the Irish language (Gaeilge). The update, which goes live today, makes Irish the 12th language supported in the daily puzzle game that has captivated millions across the globe.
Launched three years ago, Worldle has become a global phenomenon. The…
Avanti Rides Debuts in Southern Florida, Transforming How Drivers and Passengers …
Miami, FL - Avanti Rides introduces a new chapter in ride-hailing by combining passenger safety, driver empowerment, and seamless technology into a single app. Designed for the evolving needs of both drivers and riders, Avanti is delivering smarter bookings, stronger protection, and unmatched flexibility.
Built for Drivers Who Want More Than Just Rides
Avanti Rides recognizes that drivers are the foundation of the platform and offers a range of benefits focused on…
UVS-IT Unveils Guide to Choosing the Best Managed IT Services in Atlanta
Hey there, Atlanta business warriors! Have you ever felt that picking the perfect Managed IT Service is a bit like choosing the ultimate wingman for your company's tech needs? Trust me, it's not just a matter of finding someone who looks good on paper. With technology increasingly steering the ship of our businesses, selecting a reliable Managed IT Service is becoming as crucial as that morning cup of coffee we…
3D-Engineering: How 3D Scanning Services Are Revolutionizing Modern Engineering …
Imagine being able to capture every nook and cranny of an object down to the most intricate detail. Sounds magical, right? That's the power of 3D scanning services [https://3d-engineering.net/engineering-services/3d-laser-scanning-services/] in today's engineering projects. Across industries, from automotive and construction to aerospace and healthcare, 3D scanning is transforming how things are measured, mapped, and made. Whether you're designing a new building or manufacturing precision components, 3D scanning takes you from the…
More Releases for Thyroid
Rising Incidences of Thyroid Disorders Fuel Growth In The Thyroid Function Test …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Thyroid Function Test Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for thyroid function tests has witnessed substantial growth in the past few years. The market is projected to expand from $1.7 billion in 2024 to $1.81 billion in 2025, with an…
Rising Incidences of Thyroid Disorders Fuel Growth In The Thyroid Function Test …
The Thyroid Function Test Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Thyroid Function Test Market Size During the Forecast Period?
The thyroid function test market has grown significantly in recent years. It is expected to grow from $1.7 billion in 2024…
Thyroid Function Test Market Report 2024 - Thyroid Function Test Market Growth A …
"The Business Research Company recently released a comprehensive report on the Global Thyroid Function Test Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
Thyroid Ablation Devices Market
Alarming rise in prevalence of thyroid cancer, advancements in thyroid ablation system, rise in government & private funds for development of healthcare sectors, and increase in number of thyroid nodule cases are expected to notably contribute toward the growth of the global thyroid ablation devices market during the forecast period.
Rise in prevalence of thyroid cancer and thyroid nodules, demand for minimally invasive procedures, and technological advancements in ablation devices drive…
Thyroid Gland Disorders Treatment Market Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of…
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view…
